Bionique Testing Laboratories, a provider of mycoplasma testing services and part of the Asahi Kasei group, and Cellipont Bioservices, a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, have partnered to advance the adoption and validation of rapid mycoplasma detection methods in support of cGMP manufacturing for cell and gene therapies.

This collaboration will enable Cellipont to integrate rapid, validated mycoplasma detection technologies into its quality control workflows. Bionique will provide specialized mycoplasma testing services, along with tailored product-specific validation support, to ensure regulatory alignment and accelerated batch release timelines.

“This partnership with Cellipont Bioservices represents an exciting opportunity for Bionique to support the advancement of cutting-edge cell therapies,” said Gladis Zamparo, CEO of Bionique Testing Laboratories. “We are very excited to support Cellipont Bioservices in navigating the challenges—including product complexity, limited batch yields, and dynamic regulatory landscape—associated with the release testing of these novel therapies by delivering efficiency and innovation through this partnership.”

“Bionique is the gold standard when it comes to mycoplasma testing. Their unparalleled experience and collaborative approach are critical as we strengthen our QC strategies to meet the demands of modern cell and gene therapy production. We’re excited to work with a partner that shares our commitment to quality, innovation, and patient impact,” added Darren Head, CEO of Cellipont Bioservices.